Acessibilidade / Reportar erro

Active replication of hepatitis B virus (HBV) in HIV type 1 and in HIV type 2 infected patients

Replicação ativa do vírus da hepatite B (HBV) em doentes infectados pelo vírus da imunodeficiência humana (HIV) de tipo 1 ou de tipo 2

Abstracts

To evaluate the effect of concurrent infection by HIV on HBV infection or immunity, we have studied a group of 66 HIV1+ symptomatic Caucasian patients and another of 38 African HIV2+ asymptomatic individuals, concerning their HBV status: serological markers of infection and presence of HBV-DNA in serum, the last taken as sign of hepatitis B virus active replication, were monitored. HIV+ groups were compared with seronegative controls, adequately matched for age, sex and ethnological background. HBV DNA was found in 7.6% of HIV1+ Caucasian patients and 3.2% of seronegative controls; in African HIV2+ individuals 2.6% were also HBV DNA+, a percentage close to that found in HIV2 seronegative controls (2.9%). No correlation was found between HIV infection and HBV active replication. Immunodepression that follows HIV infection over time may be compatible with a degree of T cell function capable of avoiding reinfection with or reactivation of HBV, even in symptomatic stages of acquired immunodeficiency syndrome. Our findings are relevant to the choice of preventive strategies in populations at risk for HIV and HBV infection.

HIV; HBV active replication


A fim de avaliar as conseqüências da infecção por HIV no curso da infecção por HBV, ou na imunidade anteriormente adquirida, estudamos um grupo de 66 doentes Caucasóides HIV1+ sintomáticos e outro de 38 indivíduos seropositivos para HIV2 e provenientes da África, quanto a marcadores serológicos de infecção por HBV e quanto à presença de DNA viral circulante, tomada como sinal de replicação ativa do vírus da hepatite. Os grupos HIV+ foram comparados com controles seronegativos adequados tendo-se verificado que 7.6% dos doentes HIV1+ eram também HBV-DNA+ (versus 3.2% nos seronegativos) bem como 2.6% dos HIV2+ (versus 2.9% nos controles seronegativos), não sendo as diferenças estatisticamente significativas em qualquer um dos casos e não tendo sido encontrada correlação entre infecção por HIV e replicação ativa de HBV. A imunodeficiência que se instala progressivamente após infecção por HIV, poderá ser compatível com um grau de vigilância T suficiente para impedir reinfecção ou reativação de HBV, mesmo em indivíduos já sintomáticos. Os nossos resultados são relevantes para a escolha de estratégias preventivas da hepatite B em gupos com risco de infecção por HIV.


VIROLOGY

Active replication of hepatitis B virus (HBV) in HIV type 1 and in HIV type 2 infected patients

Replicação ativa do vírus da hepatite B (HBV) em doentes infectados pelo vírus da imunodeficiência humana (HIV) de tipo 1 ou de tipo 2

M.F. BarrosI; J. PiedadeII; G. NunesI; W. Canas-FerreiraII; A.P. SilvaIV; J.L. ChampalimaudIII; J.A. Machado-CaetanoI

IServiço de Imunologia, Faculdade de Ciências Médicas, Universidade Nova de Lisboa (UNL), Portugal

IIDepartamento de Microbiologia, Instituto de Higiene e Medicina Tropical (IHMT), Universidade Nova de Lisboa (UNL)

IIIUnidade de Doenças Infecciosas, Hospital Egas Moniz (IHMT, UNL)

IVMinistério da Saúde, República da Giné-Bissau

Correspondence to Correspondence to: M.F. Barros Departamento de Imunologia, Faculdade de Ciências Médicas (UNL) Campo de Santana 130 1100 Lisboa, Portugal

SUMMARY

To evaluate the effect of concurrent infection by HIV on HBV infection or immunity, we have studied a group of 66 HIV1+ symptomatic Caucasian patients and another of 38 African HIV2+ asymptomatic individuals, concerning their HBV status: serological markers of infection and presence of HBV-DNA in serum, the last taken as sign of hepatitis B virus active replication, were monitored. HIV+ groups were compared with seronegative controls, adequately matched for age, sex and ethnological background.

HBV DNA was found in 7.6% of HIV1+ Caucasian patients and 3.2% of seronegative controls; in African HIV2+ individuals 2.6% were also HBV DNA+, a percentage close to that found in HIV2 seronegative controls (2.9%).

No correlation was found between HIV infection and HBV active replication. Immunodepression that follows HIV infection over time may be compatible with a degree of T cell function capable of avoiding reinfection with or reactivation of HBV, even in symptomatic stages of acquired immunodeficiency syndrome. Our findings are relevant to the choice of preventive strategies in populations at risk for HIV and HBV infection.

Keywords: HIV; HBV active replication.

RESUMO

A fim de avaliar as conseqüências da infecção por HIV no curso da infecção por HBV, ou na imunidade anteriormente adquirida, estudamos um grupo de 66 doentes Caucasóides HIV1+ sintomáticos e outro de 38 indivíduos seropositivos para HIV2 e provenientes da África, quanto a marcadores serológicos de infecção por HBV e quanto à presença de DNA viral circulante, tomada como sinal de replicação ativa do vírus da hepatite.

Os grupos HIV+ foram comparados com controles seronegativos adequados tendo-se verificado que 7.6% dos doentes HIV1+ eram também HBV-DNA+ (versus 3.2% nos seronegativos) bem como 2.6% dos HIV2+ (versus 2.9% nos controles seronegativos), não sendo as diferenças estatisticamente significativas em qualquer um dos casos e não tendo sido encontrada correlação entre infecção por HIV e replicação ativa de HBV.

A imunodeficiência que se instala progressivamente após infecção por HIV, poderá ser compatível com um grau de vigilância T suficiente para impedir reinfecção ou reativação de HBV, mesmo em indivíduos já sintomáticos.

Os nossos resultados são relevantes para a escolha de estratégias preventivas da hepatite B em gupos com risco de infecção por HIV.

Full text available only in PDF format.

Texto completo disponível apenas em PDF.

Recebido para publicação em 13/05/1996

Aceito para publicação em 30/09/1996

  • 1. BALSANO, C.; BILLET, O.; BENNOUN, M. et al. - Hepatitis B virus X gene product transactivates HIV-LTR "in vivo". Arch. Virol., 8 (suppl.): 63-71, 1993.
  • 2. BARRÉ-SINOUSSI, F.; CHERMANN, J.C.; REY, F. et al. - Isolation of a T lymphotropic retrovirus from a patient at risk for Acquired Immunodeficiency Syndrome (AIDS). Science, 220: 868-871, 1983.
  • 3. BONINO, F.; HOYER, B.; NELSON, J. et al. - Hepatitis B virus DNA in the sera of HBsAg carriers: a marker of active virus replication in the liver. Hepatology, 1: 386-391, 1981.
  • 4. BERTOLETTI, A.; SETTO, A.; CHISANI, F.V. et al. - Natural variants of cytotoxic epitopes are T cell receptor antagonists for antiviral cytotoxic T cells. Nature, 269: 407-410, 1994.
  • 5. BRÉCHOT, C.; HADCHOVEL, M.; SCOTTO, J. et al. - Detection of hepatitis B virus DNA in liver and serum: a direct appraisal of the chronic carrier state. Lancet, 2: 765-767, 1981.
  • 6. CARMAN, W.F.; JACYNA, M.; HADZYANNIS, S. et al. - Mutation preventing formation of hepatits B e antigen in patients with chronic hepatitis B infection. Lancet, 2: 588-590, 1989.
  • 7. CDC-Centers for Disease Control - Classification system for human T lymphotropic virus type III / lymphoadenopathy associated virus infection. Ann. intern. Med., 105: 234-237, 1986.
  • 8. CISTERNA, R.; CAMPELO, C.; GORRINO, T. et al. - Association between HIV and other DNA virus "in vitro". Eurp. J. clin. Microbiol. infect. Dis., 14: 591-596, 1995.
  • 9. CLAVEL, R.; GUYADER, M.; GUÉTARD, D. et al. - Isolation of a new human retrovirus from West African patients with AIDS. Science, 233: 343-346, 1986.
  • 10. DANE, D.S.; CAMERON, C.H. & BRIGGS, M. - Virus - like particles in serum of patients with Australia antigen associated hepatitis. Lancet, i: 695-698, 1970.
  • 11. DELFINI, C.; GARBUGLIA, A.R.; ALTANI, E. et al. - Heroin addicts infected by HBV and HIV have a low prevalence of HBV DNA in peripheral blood mononuclear cells. J. med. Virol., 41: 114-119, 1993.
  • 12. DUSHEIKO, G.M.; SHER, R. & WELLS, C. - Concurrent human immunodeficiency and hepatitis B virus exposition in Southern Africa. In. INTERNATIONAL SYMPOSIUM ON VIRAL HEPATITIS AND LIVER DISEASE, London, 1987, A30, 11A.
  • 13. FRANCISCID; BALDELI, E.; PAPILI, R.et al. - Prevalence of HBV, HDV, and HCV hepatitis markers in HIV-positive patients. Europ. J. Epidem., 11: 123-126, 1995.
  • 14. GILSON, R.J.; TEDDER, R.S. & WELLER, I. - Hepatitis B reactivation or reinfection associated with HIV infection. Lancet, 2: 1330, 1989.
  • 15. GOLDIN, R.D.; FISH, D.E.; HAY, A. et al. - Histological and immunohistochemical study of hepatitis B virus in human immunodeficiency virus infection. J. clin. Path, 43: 203-205, 1990.
  • 16. HOUSSET, C.; POL, S.; CARNOT, F. et al. - Interaction between human immunodeficiency virus 1, hepatitis delta virus and hepatitis B virus infection in 260 chronic carriers of hepatitis B virus. Hepatology, 15: 578-583, 1992.
  • 17. ILTIS, J.P.; PATEL, N.M.; LEE, S.R. et al. - Comparative evaluation of an immunofluorescent antibody test, enzyme immunoassay and western blot for the detection of HIV 1 antibody. Intervirology, 31: 122-128, 1990.
  • 18. KANEKO, S.; MILLER, R.H.; FEINSTONE, S.M. et al. - Detection of serum hepatitis B virus DNA in patients with chronic hepatitis utilizing the polymerase chain reaction assay. Proc. nat. Acad. Sci. (Wash.), 86: 312-316, 1989.
  • 19. KANEKO, S. & MILLER, R.H. - Characterization of primeis lor optimal amplification of Hepatitis B virus DNA in the polymerase chain reaction assay. J. virol. Meth., 29: 225-230, 1990.
  • 20. KASHAKA, O.; MUBIKAI, L.; KAYEMBE, K. et al. - Hepatitis B virus activation among Central Africans infected with human immunodeficiency virus (HIV) type 1: pre-s2 antigen is predominantly expressed in HIV infection. J. infect. Dis., 169: 628-632, 1994.
  • 21. KOBLIN, B.; TAYLOR, P.E.; RUBINSTEIN, P. et al. - Effect of duration of hepatitis B virus infection on the association between human immunodeficiency virus type 1 and hepatitis B viral replication. Hepatology, 15: 590-592, 1992.
  • 22. LEVRERO, M.; BALSANO, C.; NATOLI, G. et al. - Hepatitis B virus X protein transactivates the long terminal repeal of human immunodeficiency virus type 1 and 2. Virology, 64: 3082-3086, 1990.
  • 23. McDONALD, J. A.; CARUSO, L.; KARYANIS, P. et al. - Diminished responsiveness of male homosexual chronic hepatitis B virus carriers with HTLV III antibodies to recombinant a-interferon. Hepatology, 7: 719-723, 1987.
  • 24. McDONALD, J.A.; HARRIS, S.; WATERS, J. et al. - Effect of human immunodeficiency virus (HIV) infection on chronic hepatitis B viral antigen display. J. Hepat., 4: 337-342, 1987.
  • 25. SAIKI, R.K.; GEFLAND, D.H.; STOPPER, S.J. et al. - Primer directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science, 239: 487-491, 1988.
  • 26. SCOTTO, J.; HADCHOVEL, M.; HEY, C. et al. - Detection of hepatitis B virus DNA in serum by a simple spot hybridization technique. Comparison with results for other viral markers. Hepatology, 3: 279-284, 1981.
  • 27. TWU, J.S.; WU, J.Y. & ROBINSON, W.S. - Transcriplional activation of the human immunodeficiency virus type 1 long terminal repeat by hepatitis B virus X protein requires "de novo" protein synthesis. Virology, 177: 406-410, 1990.
  • 28. VENTO, S.; DILENI, F.; GAROFENO, T. et al. - Reactivation of Hepatits B in AIDS. Lancet, 2: 108-109, 1989.
  • 29. WELLER, I.V.; FOWLER, M.J.; MONJARDINO, J. & THOMAS, H.C. - The detection of HBV-DNA in serum by molecular hybridisation: a more sensitive method for the detection of complete HBV particles. J. med. Virol., 9: 273-280, 1981.
  • Correspondence to:

    M.F. Barros
    Departamento de Imunologia, Faculdade de Ciências Médicas (UNL)
    Campo de Santana 130
    1100 Lisboa, Portugal
  • Publication Dates

    • Publication in this collection
      22 Sept 2006
    • Date of issue
      Aug 1996

    History

    • Accepted
      30 Sept 1996
    • Received
      13 May 1996
    Instituto de Medicina Tropical de São Paulo Av. Dr. Enéas de Carvalho Aguiar, 470, 05403-000 - São Paulo - SP - Brazil, Tel. +55 11 3061-7005 - São Paulo - SP - Brazil
    E-mail: revimtsp@usp.br